Navigation Links
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Date:5/11/2009

RM-1 trial as an oral late breaker at the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. This is the first study to investigate the activity of a combination of two oral antiviral molecules to treat HCV in the absence of interferon. The study is investigating the combination of Pharmasset's R7128, a nucleoside inhibitor, with InterMune's R7227, a protease inhibitor;
  • On April 24, 2009, Pharmasset announced that its development partner, Roche, had initiated dosing of patients in the phase 2b trial of R7128 in combination with the standard of care in genotype 1 and 4 HCV infected patients. The start of the trial triggered a $10.0 million milestone payment to Pharmasset that is expected to be received in the quarter ending June 30, 2009;
  • On April 20, 2009, Pharmasset announced that it had voluntarily halted its phase 3 registration studies of clevudine for the treatment of chronic hepatitis B infection;
  • On March 31, 2009, Pharmasset announced the dosing of the first healthy volunteer in the phase 1 trial with PSI-7851, a second generation nucleotide inhibitor of HCV.

  • "Our HCV pipeline continues to make solid progress," stated Schaefer Price, President and Chief Executive Officer. "In April, we announced exciting data from the INFORM-1 trial at EASL and the initiation of the phase 2b trial with R7128. We are now able to increase our focus on further strengthening our portfolio of HCV nucleos(t)ides with the decision to halt registration studies with clevudine. We look forward to providing the first antiviral data on PSI-7851 in the second half of 2009."

    Calendar Year 2009 Anticipated Milestones:

    • Announce selection of candidate(s) from our purine series of nucleos(t)ide analog for HCV in second half of 2009;
    • Provide update on safety from first 100 patients in t
      '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
    3. Pharmasset Accesses up to $30 Million of Working Capital
    4. Pharmasset to Present at Three Investor Conferences in November 2007
    5. Pharmasset Appoints Michael Rogers as Chief Development Officer
    6. Pharmasset Reports Fiscal Year End 2007 Financial Results
    7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
    8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
    9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
    10. Pharmasset Appoints Herbert J. Conrad as a Director
    11. Pharmasset Receives $10 Million of Working Capital
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
    (Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
    (Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
    (Date:7/24/2014)... Calif. , July 24, 2014 SRI ... contract with the National Institute of Allergy and Infectious ... to conduct preclinical development of potential therapies for HIV ... drugs to treat HIV and AIDS and the complications ... as microbicides for preventing sexual transmission of HIV. ...
    Breaking Biology Technology:Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
    ... BASEL, Switzerland, April 17 Syngenta today,announced that it ... in,Beijing, China. Its focus will be on early-stage evaluation ... corn and soy, in the areas of yield,improvement, drought ... facility will have a global scope and will complement,Syngenta,s ...
    ... NexGenix Pharmaceuticals, presented,data on its Hsp90 inhibitor program ... San Diego today. The company presented data in ... novel, radicicol-based,Hsp90 inhibitors in its compound series., ... models,without evidence for liver and kidney toxicity. The ...
    ... Offers a Complete Solution for the Study of ... ... (Nasdaq:,SIAL) today announced the launch of its Imprint(TM) Chromatin,Immunoprecipitation Kit ... a complete,solution for Chromatin Immunoprecipitation, including columns and reagents,for DNA ...
    Cached Biology Technology:Syngenta To Build Major Global Biotech Research Center in Beijing, China 2Syngenta To Build Major Global Biotech Research Center in Beijing, China 3NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 2Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 3
    (Date:7/24/2014)... how wildlife loss leads to conflict among people around ... Conservation Society (WCS) Health & Ecosystems: Analysis of Linkages ... interdisciplinary approach to tackle global biodiversity decline. , The ... the world,s people and provides protein for more than ... as no surprise that today,s unprecedented loss of wildlife, ...
    (Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
    (Date:7/24/2014)... native animal species for food or commercial food sale, ... in the decline of many species of primates and ... more than half of the species being consumed are ... surveying not only the meat made available for sale ... forest by hunters and brought to villages for consumption, ...
    Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
    ... plants is determined by pigments such as aurones, anthocyanins, ... displayed is dependent not only on the pigment present, ... of metal ions, and pH, among others. Information about ... plant geneticists to engineer new hues, adding to the ...
    ... hunted to local extinction more than a century ago and ... whales of mainland New Zealand are coming home. A ... that whales from a small surviving population around remote, sub-Antarctic ... mainland. Before the onslaught of 19th century whaling, historical ...
    ... Mary, University of London, sheds new light on why people ... suffer organ damage in parts of the body which are ... in Nature Immunology *, examines the way certain white ... defend damaged organs against injury or infection. This is ...
    Cached Biology News:Engineering blue-hued flowers 2Fighting back from extinction, New Zealand right whale is returning home 2Fighting back from extinction, New Zealand right whale is returning home 3Rogue blood cells may contribute to post-surgery organ damage 2
    Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
    Request Info...
    Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
    Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
    Biology Products: